Interleukin-3 (IL-3) and stem cell factor (SCF) are important mast cell growth and differentiation factors. Since both cytokines activate the transcription factor Stat5, a known regulator of proliferation and survival, we investigated the effects of Stat5 deficiency on mast cell development and survival. Bone marrow-derived mast cell 
Introduction
In asthma and allergy, mast cell activation provides an environment in the connective and mucosal tissues conducive to chronic inflammation and resulting pathology (Reviewed in 1). A role for mast cell activation has also been shown in animal models of multiple sclerosis (2) , rheumatoid arthritis (3) and coronary artery disease (4) .
However, recent data challenge the dogma of a pathological role for mast cell activation, demonstrating its importance to innate immunity (Reviewed in 5). These data make our understanding of mast cell biology more crucial than ever.
Critical aspects of mast cell biology have been brought to light through use of naturally occurring and targeted genetically-deficient rodents. Data from these studies implicated stem cell factor (SCF) and IL-3 in rodent mast cell development (reviewed in 1, 6, 7). SCF and its receptor, Kit, are essential for normal mast cell development. In contrast, Lantz and co-workers demonstrated that IL-3 is dispensable for mast cell development, but is required for normal mast cell expansion during immune responses to intestinal pathogens (8).
SCF and IL-3 induce signal transduction through several pathways, including phosphoinositol 3'-kinase (PI3-K), phospholipase C, protein kinase C, the Ras-MAP kinase (MAPK) cascade, Janus (Jak) kinases, and signal transducers and activators of transcription (Stats). The relative importance of each pathway in mast cell development, survival, and proliferation is incompletely understood. Several studies have addressed these questions through use of primary bone marrow-derived mast cell (BMMC)
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From populations or cell lines. The sum of these studies implicates PI3-K, Ras-MAPK, and Stat5 in IL-3-and SCF-induced survival and/or proliferation (9-12).
While SCF has been shown to activate both Stat1 and Stat5, we find that in mast cells, only Stat5 DNA binding activity is elicited by SCF. In contrast, IL-3 activates both Stat3 and Stat5 in mast cells (13, 14, 15) . Given the unique role of SCF in mast cell development, and its selective activation of Stat5, we designed experiments to assess the role of Stat5 in mast cell biology. Using in vivo and in vitro approaches, we find that Stat5 expression is an essential aspect of mast cell development, survival, and proliferation. These data emphasize the importance of Stat5 in IL-3 and SCF signal transduction, especially with respect to the mast cell lineage.
Materials and Methods
Derivation of BMMC Populations -BMMC were derived from 6-12 week old C57BL/6x129 mice, (Taconic Farms, Germantown, NY), or from C57BL/6x129 STAT5-A/B +/-or -/-mice (the kind gift of James Ihle, Memphis, TN) (16) . BMMC were prepared by culturing unseparated bone marrow cells at 5x10 5 
cells/ml in complete RPMI
supplemented with IL-3 (5ng/ml) and SCF (50ng/ml) for three weeks. Mast cell phenotype was confirmed by flow cytometry analysis with antibodies specific for Kit, IgE, CD13, Fc RII/RIII or T1/ST2, and by histochemical staining with toluidine blue at acid pH for 30 minutes. At the time of use, BMMC cultures were >99% mast cells.
BMMC were maintained in culture for up to six months, but were generally used in the first three months of culture.
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From Cytokines, Antibodies, and Flow Cytometry -Murine IL-3 and SCF were purchased from R&D Systems (Minneapolis, MN). Fluoresceinisothiocyanate (FITC)-conjugated rat antiKit, rat anti-CD13, rat anti-Fc RII/RIII, and mouse IgE were purchased from BD Pharmingen (San Diego, CA). FITC-labeled rat anti-mouse IgE was purchased from Southern Biotechnology (Birmingham, AL). FITC-labeled rat anti-mouse T1/ST2 was purchased from Morwell Diagnostics (Switzerland). Flow cytometry was performed using a Becton Dickinson FACScan equipped with CellQuest software (BD Pharmingen, San Jose, CA).
Apoptosis Analyses -For analysis of mast cell apoptosis, BMMC were cultured at 3x10 5 cells/ml in the indicated cytokines and conditions. Cells were assessed for sub-diploid DNA content by propidium iodide staining after cell fixation (PI-DNA staining) as described (12). To assess cell numbers in some cultures, cells cultured under identical conditions were analyzed in triplicate by flow cytometry with automated counting for a pre-set time (45 seconds per sample, with 0.1 second resolution). Live cell counts included all cells not in the sub-diploid DNA region. Di(OC 6 ) 3 was purchased from Molecular Probes (Eugene, OR) and used according to the manufacturer's specifications.
CaspaTag-3 and -9 kits were purchased from Intergen (Purchase, NY).
Stat5
Transfection and Transduction -Stat5 A/B-deficient BMMC were transfected with mouse Stat5A cDNA expressed in pIRES.EGFP by electroporation at 400V, 500µF.
GFP-positive cells were isolated by cell sorting after 48 hours of culture. For Stat5 transduction experiments, bone marrow cells from wild-type C57Bl/6 mice were preFor personal use only. on July 16, 2017 . by guest www.bloodjournal.org From stimulated for 2 days in DMEM/15% fetal bovine serum with recombinant murine IL-3 (20 ng/ml), recombinant human IL-6 (50 ng/ml), and recombinant mouse SCF (50 ng/ml). Cells were then transduced by co-culture on irradiated retroviral ecotropic producer cells for an additional two days in the presence of the same growth factors and polybrene (6 mg/ml). The cells were then removed and expanded in IL-3 and SCF to establish BMMC cultures. Stat5A or Stat5A 757 transcription from the bicistronic retroviral vectors was driven by the murine stem cell virus (MSCV) long-terminal repeat.
The vectors also included an internal ribosomal entry sequence (IRES) to initiate translation of a downstream GFP gene from the same mRNA.
RNase protection assay (RPA) analysis -Total RNA harvested from 5-10x10 6 cells was subjected to RPA analysis using the RiboQuant System (BD Pharmingen, San Diego, CA) according to the manufacturer's specifications.
Western Blot Analysis -Whole cell lysates were prepared and analyzed as described previously (12). Anti-cyclin D3 and anti-Bcl-x were purchased from BD Transduction Laboratories (San Diego, CA). Anti-cyclin A, anti-cyclin B1, anti-bcl-2, anti-actin, and horse radish peroxidase-conjugated secondary antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA).
Cell cycle progression analysis -For bromodeoxyuridine (BrdU) measurements of cell cycle progression, BMMC were incubated without cytokines for 16 hours, then cultured as indicated for 48 hours. BMMC were then incubated with 10mM bromodeoxyuridine Statistical Analysis -Analyses of variance were performed at = 0.05 using Statmost software (DataMost, Salt Lake City, UT). Student's T test was performed using SysStat9 software.
Results
Stat5 is essential for in vitro mast cell development. Given evidence of Stat5 involvement in IL-3 and SCF signaling, we attempted to derive BMMC populations from mice deficient in both Stat5A and Stat5B (hence referred to as Stat5-deficient).
However, Stat5-deficient bone marrow cells died rapidly when cultured in WEHI-3 cellconditioned medium, conditions that normally support BMMC ( Figure 1A) . Similarly, expressing a dominant negative Stat5A (Stat5A 757) in wild type bone marrow cells greatly decreased cell proliferation in response to IL-3+SCF, though mast cell differentiation did occur ( Figures 1B, 1C) .
As with the studies using Stat5A 757 gene transfer into wild type bone marrow cells, Stat5-deficient BMMC populations could be derived in recombinant IL-3+SCF.
The resulting BMMC populations had a normal granulated mast cell morphology and expressed surface markers consistent with the mast cell lineage, including Fc RI, Kit, T1/ST2, and Fc RII/RIII, at levels comparable to wild type BMMC ( Figure 1D and data not shown). Like their wild type counterparts, Stat5-deficient BMMC could be stably cultured for up to 6 months in IL-3 +SCF. After deriving these BMMC cultures, we assessed their growth in IL-3 or SCF alone. Neither wild type nor Stat5-deficient BMMC could be maintained in SCF alone for long periods, as it appears to function largely as a co-mitogen for these cells (data not shown). In contrast, wild type BMMC could be Figure 1E ). It appears that Stat5 is critical to the survival and expansion of developing mast cells.
Defective IL-3-and SCF-induced survival signaling in Stat5-deficient BMMC.
IL-3 and SCF are potent stimulators of mast cell survival, and prevent factor-withdrawalinduced apoptosis (reviewed in 17). Moreover, gain-of-function c-Kit mutations are frequently observed in apoptosis-resistant, factor-independent mastocytomas (18) . Stat5 function has been associated with control of survival and proliferation (19) (20) (21) (22) ). Since we found a defect in Stat5-deficient BMMCs when attempting to culture them for long periods, we assessed their survival more precisely using short-term survival assays.
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From for 48 hours, and apoptosis was assessed by the presence of sub-diploid DNA after PI-DNA staining ( Figure 2 ). While IL-3+SCF allowed survival of both groups, cultures with single cytokines showed significantly different concentration-response curves.
Calculation of half-maximal concentrations needed to prevent apoptosis revealed an approximate 80-fold difference in IL-3-induced signaling, and a 50-fold difference in SCF-induced survival signaling.
Stat5-deficient BMMC cultured in SCF or IL-3 demonstrate mitochondrial
damage. The loss of survival signaling observed with Stat5-deficient BMMC was reminiscent of factor withdrawal-induced apoptosis. This process has been shown to proceed through a mitochondrial mechanism, with loss of Bcl-x(L) and Bcl-2 expression in some cells (23-25). We therefore assessed expression of Bcl-2 and Bcl-x(L) during culture in IL-3+SCF (positive control for survival) or in conditions where IL-3 (.02ng/ml) or SCF (10ng/ml) alone were at limiting concentrations. Using IL-3+SCF cultures as reference survival controls for each population, we found that both wild type and Stat5-deficient BMMC reduced Bcl-2 and Bcl-x(L) expression after culture in IL-3 or SCF alone, but that this reduction was more pronounced in Stat5-deficient populations ( Figure   3A ). Importantly, these mRNA data were matched by a total loss of detectable Bcl-2 and
Bcl-x(L) protein in Stat5-deficient BMMC after 36 hours of culture in IL-3 or SCF alone, as judged by western blotting ( Figure 3B ).
In keeping with reduced Bcl-2 and Bcl-x(L) expression, we observed a greater loss of mitochondrial membrane potential and a greater activation of caspases -9 and -3 Table I ). Hence by two in vivo analyses, the absence of Stat5 appears to result in mast cell deficiency.
Although the maturation and survival defects we observed in Stat5-deficient BMMC offer the most likely explanation for the in vivo mast cell deficiency, an alternative explanation is reduced growth factor production due to loss of Stat5. We assessed this possibility by measuring IL-3 and SCF levels in bone marrow and peritoneal fluid, the tissues where all mast cells begin their development or where many reside, respectively. As shown in Table 2 , IL-3 and SCF concentrations in these tissues were consistently low, well below the ng/ml concentrations used in vitro. Importantly, only one measure, reduced IL-3 levels in the peritoneal fluid of Stat5-deficient mice, Unfortunately, we find Stat5-deficient BMMC to be very poor transfection subjects, making reporter assay systems difficult to employ. What we can say with certainty is that In place of a cyclin D defect, our RPA and western blot analyses found reduced expression of the downstream cyclins A and B. The lack of cyclin A induction was consistent with the delayed S phase transition we observed. These results indicate that Stat5 expression is required for normal cyclin A induction, but that a delayed induction is possible through a Stat5 -independent pathway. This entry into S phase appeared to be at best a faltering one, since Stat5-deficient BMMC could not be maintained in IL-3 alone (Figure 1) . It is interesting to note that Stat5-deficient bone marrow has been found to have a poor competitive repopulating ability in transplantation assays (36, 37), and that bone marrow populations enriched stem cells are 10-fold less responsive to IL-3+SCF stimulation than wild type cells (38). These results also fit with a defect in cell cycle Control cultures were maintained in IL-3 (5ng/ml)+SCF (50ng/ml). Total RNA was subjected to RPA analysis. For each culture, the ratio of Bcl-x(L) or Bcl-2 expression to the GAPDH and L32 loading controls was determined. These ratios were then used to 
